Several possible studies
Story checked
Inhaled drug shows promise for rare lung disease combination (opens in a new tab)
medicalxpress.com · 2026-09-26
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Inhaled drug shows promise for rare lung disease combination
medicalxpress.com · 2026-09-26
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Cited as backgroundpresented as the new finding
Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH
Thorax · 2026
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedMosliciguat, an investigational inhaled soluble guanylate cyclase (sGC) activator, has produced marked and consistent effects in a randomized phase 2 study involving patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedAt week 16, the PHocus study met its primary endpoint with a 56.3% placebo-adjusted reduction in pulmonary vascular resistance.View evidenceHide evidence
As stated56.3% placebo-adjusted reduction in pulmonary vascular resistance
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedSix-minute walking distance improved by 35.2 meters versus placebo at week 16 and, in a prespecified exploratory analysis, the placebo-adjusted difference increased to 52.7 meters at week 24; improvements were also observed in NT-proBNP and other measures of right-heart and pulmonary vascular function.View evidenceHide evidence
As stated35.2 meters at week 16; 52.7 meters at week 24
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedThe article says a phase 3 trial, PHrontier, is already underway to further test mosliciguat in PH-ILD.View evidenceHide evidence
As statedapproximately 375 patients planned
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe article notes earlier phase 1b ATMOS results in PAH/CTEPH showed sustained reductions in pulmonary vascular resistance after a single inhaled dose of mosliciguat, with mostly mild adverse events and no safety-relevant changes in systemic vascular resistance or blood pressure.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 31 candidate papers
Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH
Thorax · 2026 · PubMed, Crossref
Journal club
Thorax · 2026 · Crossref
Author response for "Electron energy distribution measurement in an inductively coupled plasma with a cryogenic temperature substrate"
2026 · Crossref
Author response for "Beyond Misconceptions: Idealisation Boundaries and the Persistent Difficulty of Quantitative Chemistry"
2026 · Crossref
A multisystem mystery…
Thorax · 2026 · Crossref
And 26 more candidates considered.